Latest News

Kalbe Group Receives The Karya Anak Bangsa Award From The Ministry of Health

Kalbe Group Receives The Karya Anak Bangsa Award From The Ministry of Health

Jakarta, November 8, 2018 - PT Kalbe Farma Tbk. (Kalbe) through its subsidiary PT Kalbio Global Medika today received an award from the Ministry of Health and is the Recipient of the Karya Anak Bangsa Award from the Ministry of Health of the Republic of Indonesia. The award was presented by the Minister of Health, Prof. Dr. dr. Nila Djuwita F. Moeloek SpM (K) to the President Director of PT Kalbe Farma Tbk Vidjongtius alongside the opening of the 2018 Domestic Health Products and Development Exhibition in commemoration of the 54th National Health Day at the Indonesia Convention Exhibition, BSD Tangerang. 

"Kalbe as an Indonesian-owned company is committed to make a real contribution to the development of the pharmaceutical industry in Indonesia." said Vidjongtius, President Director of PT Kalbe Farma Tbk. "PT Kalbio Global Medika which produces raw materials and biological products is an innovation and is part of the technological leap, especially biotechnology, has an important role in the future for the pharmaceutical industry," Vidjongtius continued.


 PT Kalbio Global Medika (KGN) that was inaugurated by the President of the Republic of Indonesia, Ir. H. Joko Widodo, in 27 February 2018, has recently obtained the Good Manufacturing Method of Active Drugs Ingredients (CPBBAOB) and Good Drugs Manufacturing Method (CPOB) from the National Food and Drugs Monitoring Agency (BPOM) and its products are ready to be marketed by the end of year 2018.

KGM will be producing Erythropoietin (EPO) that is a crucial ingredient in dialysis and cancer medications.  The product is aimed to fulfill domestic needs and planned to be exported to ASEAN markets as well as several other countries. Aside of Erythropoietin, KGM will also manufacture Granulocyte Colony Stimulating Factor (GCSF) that is a medication to increase the production of granulocyte, as well as products with new molecule called Efepoietin (Long Acting EPO) that has the function to stimulate the forming of red blood cells.  Next the company plans to produce insulin and several MAb (Monoclonal Antibodies) products for the treatment of cancer.

PT Kalbio Global Medical has the facility to produce biological drugs (biosimilar and biobetter) that is located in the industrial area of the Delta of Silicon Cikarang and stands on a 11,000 sqm of land.  The factory has the advantage of most recent technological advantages, quality system and international-standard facilities as well as environmentally friendly.

In year 2017 KGM managed to achieve several prestigious awards including Facility of the Year Award (FOYA) for category Honorable Mentions that was awarded by the International Society for Pharmaceutical Engineering. And crowned as "The most promising new biologics facility" by IMAPAC, an organization to help businesses worldwide to generate real growth and increase awareness of their social impact for the community.

In addition to the Karya Anak Bangsa award from the Ministry of Health, Kalbe is also participating in the 2018 Domestic Health Products and Development Exhibition. In this exhibition Kalbe Group involved several of its subsidiaries to promote their products; including PT Kalbio Global Medika which produces raw materials for medicines and biological products, PT Bintang Toedjoe with Bintang Toedjoe Masuk Angin products; Kalbe Nutritionals with products that meet the daily nutritional needs of children up to adults such as Entrasol, Diabetasol, Fitbar, Nutrive Benecol and Diva; PT Hexpharm Jaya with generic blue packaging products, PT Saka Farma which produces over-the-counter drugs, one of which is a vitamin for children, Cerebrofort; PT Enseval Medika Prima that is engaged in marketing medical devices, Kalbe Beverages which produces healthy drinks that can be consumed daily such as Veggie Fruit products, Original Love Juice and Hydro Coco.

Kalbe at a glance

PT Kalbe Farma Tbk ("Kalbe") was established in 1966 and is one of the biggest public pharmaceutical companies in Southeast Asia. Kalbe has four main divisions that handle reliable and varied brand portfolio: prescription medicines (Cefspan, Brainact, Broadced, etc.); over-the-counter medication division (Woods, Promag, Mixagrip, Komix, Fatigon, etc.); health drinks (Hydro Coco, Extra Joss, Nitros); nutrition division (ChilKid, Prenagen, Diabetasol, etc.); and distribution division. Kalbe currently has more than 35 subsidiaries, 14 production facilities with international standard, and employs more than 17,000 employees dispersed across more than 72 branches throughout Indonesia. From 1991, Kalbe is listed at Indonesia Stock Exchange (IDX: KLBF).

521 Rate this article:
No rating

Please login or register to post comments.